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Ovarian cancer is the fifth most common cancer among U.S.women.1 An estimated 23,400 new cases were expected to be
diagnosed in the U.S. in 2001. As is the case for breast and endo-
metrial cancers, ovarian cancer is more common among women in
northern and central Europe, and North America compared with
Africa, South America, and Asia.2 In the U.S., substantial racial and
ethnic variations also are observed in the incidence of ovarian
cancer. rates reportedly are highest among non-Hispanic white
and American Indian women, and are lower among Hispanic,
Native Hawaiian, and Asian women.3 Among white women in the
U.S., there has been a gradual decline in the incidence and mor-
tality from ovarian cancer since 1973, whereas rates among black
women during this time period have been fairly stable.4 The epi-
demiology of ovarian cancer was discussed in the article by Good-
man and How.5
MATERIALS AND METHODS
The North American Association of Central Cancer Registries
(NAACCR) data file for the period 1992–1997 contains information
regarding 67,746 women diagnosed with incident ovarian cancer,
including 61,003 white women, 4106 black women, 187 American
Indian women, and 1898 Asian/Pacific Islander women. Hispanic (n
 3665) or Not Hispanic (n  36,106) identification was obtained
from a subset of 40,384 women with ovarian cancer (60%). Informa-
tion regarding the summary stage of the ovarian cancer at the time of
diagnosis was available for 55,814 (82%) of the total cases. Cases were
subdivided into women with malignant disease (n  59,277) and
women with ovarian cancer of low malignant potential (n  8469). A
description of the selection of these cases is described elsewhere in
this supplement.5
We calculated an average annual incidence rate, which is the
sum of the number of new cases of ovarian cancer reported to
NAACCR between 1992–1997 divided by the sum of the annual
denominators. All rates were age-adjusted by 5-year age groups,
unless otherwise indicated. The 1970 U.S. population was used for
age standardization. Relative percentages also were computed as
the age-adjusted incidence rate for a particular subgroup (e.g.,
borderline malignancies) divided by the age-adjusted incidence
rate for all subgroups (e.g., all malignancies), which is the approx-
imate sum of the age-adjusted incidence rates across all subgroups
combined.
2676
Published 2003 by the American Cancer Society*
DOI 10.1002/cncr.11349
RESULTS
Black, American Indian, Asian/Pacific Islander, White
The overall incidence of ovarian cancer rose with in-
creasing age up to the age of 75–84 years, before declin-
ing slightly among women ages  80–85 years. Ovarian
cancer incidence in Asian/Pacific Islander women
climbed more gradually than the rates for black and
white women (Fig. 1). (Too few American Indian women
were identified for age-specific rates to be calculated.)
Among women ages 15–24 years, the incidence rates
among Asian/Pacific Islander women were higher than
those in white and black women. Among women age
 25 years, incidence rates were highest among white
women. Asian/Pacific Islander women experienced
higher rates of ovarian cancer than black women up to
the age of 60 years. In women age  60 years, the
age-specific rates were higher among black women than
among Asian/Pacific Islander women.
White women had the highest age-adjusted in-
cidence rate for malignant ovarian cancer (13.1 per
100,000) among all racial and ethnic groups. The
risk of ovarian cancer among white women was 28%
higher than the risk in American Indian women,
46% higher than the risk in black women, and 56%
higher than the risk in Asian/Pacific Islander women
(Table 1).
The age-specific incidence of borderline ovarian
cancer was somewhat different from the incidence of
malignant cancer, with a more gradual increase re-
ported with age for each racial and ethnic group (Fig.
2). The incidence among white women was similar to
that among Asian/Pacific Islander women up to age 25
years, peaked at ages 45–59 years, and then declined
gradually thereafter. The rate of borderline tumors
increased more gradually in adulthood among Asian/
Pacific Islander women than among white women,
peaking at ages 70 –74 years and then again after the
age of 85 years. Among black women, the incidence of
borderline tumors generally was lower than that for
white and Asian/Pacific Islander women until peaking
at ages 65– 69 years, when the incidence rate ap-
proached that of white women.
Nearly 13% (n 8469) of reported ovarian cancers
were borderline or of low malignant potential, with an
overall age-adjusted incidence rate of 2.0 per 100,000
(Table 2). The ethnic-specific incidence rates for ovar-
ian cancer of low malignant potential paralleled those
for all ovarian cancer combined; rates were highest
among white women, followed by Asian/Pacific Is-
lander and black women. The relative percentage of
these borderline tumors to the incidence of all inva-
sive ovarian cancers combined was similar across eth-
nic groups, varying between 12–14%.
Serous carcinoma was the most common histo-
logic type among all racial and ethnic groups, followed
FIGURE 1. Age-specific incidence rates for malignant ovarian cancer by
race, North American Association of Central Cancer Registries (NAACCR), U.S.
combined data, 1992–1997.
TABLE 1
Malignanta Ovarian Cancer Counts and Age-Adjusted Incidence
Ratesb by Race, Selected Areas in the U.S., 1992–1997c
Race Count Rate Lower CI Upper CI
White 53,496 13.1 13.0 13.2
Black 3589 9.0 8.7 9.3
American Indiand 81 10.2 8.0 12.7
Asian/Pacific Islander 1596 8.4 8.0 8.9
All Racese 59,277 12.6 12.5 12.7
CI: 95% confidence intervals.
a Malignant is not equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462: papillary
serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystadenoma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Source: North American Association of Central Cancer Registries file submissions as of December
1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta),
Florida, Idaho, Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit), Minnesota, Montana,
Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington
(Seattle), West Virginia, and Wisconsin.
d American Indian includes cases from Arizona and New Mexico only.
e Total includes 435 women with other or unknown race and 80 American Indian women in areas
outside Arizona and New Mexico.
FIGURE 2. Age-specific incidence rates for borderline ovarian cancer by
race, North American Association of Central Cancer Registries (NAACCR) U.S.
combined areas, 1992–1997.
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by mucinous, endometrioid, and clear cell carcinomas
(Table 3). The risk of serous carcinoma among white
women (4.8 per 100,000) was 45% higher than among
American Indian women (3.3 per 100,000) and was
92% higher than among black and Asian/Pacific Is-
lander women (2.5 per 100,000). The rates for muci-
nous, endometrioid, and clear cell carcinomas were
lower in black women compared with white and
Asian/Pacific Islander women. The rates of sex cord
and germ cell histologic types of ovarian cancer were
similar among all ethnic groups for which sufficient
information existed. The age-adjusted rate of unspec-
ified cancer accounted for a larger percentage of over-
all ovarian malignancy among black women (4.4%)
than among white women (3.1%) or Asian/Pacific Is-
lander women (2.4%). Unspecified carcinoma and ad-
enocarcinoma, not otherwise specified (NOS) also
were relatively more common among black women as
a percentage of their total ovarian cancer rate.
Histologic-specific rates of borderline ovarian tu-
mors were found to differ substantially by racial and
ethnic group (Table 4). Papillary serous cystadenoma
was the most common borderline tumor among white
women, followed by mucinous cystadenoma, serous
cystadenoma, papillary mucinous cystadenoma, and
papillary cystadenoma. Papillary serous cystadenoma
also was the most common borderline tumor among
black women, but mucinous cystadenoma was less
common than serous cystadenoma. Mucinous cysta-
denoma was the most frequent borderline tumor
among Asian/Pacific Islander women with a rate of 0.8
per 100,000, which is 14% higher than the rate for this
histologic type among white or black women. By con-
trast, the rate for papillary serous cystadenoma (0.3
per 100,000) was relatively low among Asian/Pacific
Islander women and represented a far smaller per-
centage (21%) of borderline tumors than among white
women (35%) and black women (42%).
Distant or metastatic carcinoma was the most
common stage at diagnosis among all racial and eth-
nic groups, followed by localized and regional disease
(Table 5). White women were found to have the high-
est rate of ovarian cancer in each stage group. How-
ever, American Indian women had the highest rate of
distant stage cancer relative to their overall ovarian
cancer incidence rate (72%). The lowest rate of distant
cancer was found in Asian/Pacific Islander women
(3.3 per 100,000); these women had the highest rate of
localized cancer relative to their overall cancer inci-
dence (1.5/5.9  25%). The age-adjusted rate of un-
staged relative to staged cancers was considerably
higher among black and white women than among
Asian/Pacific Islander women.
The majority of borderline tumors were diagnosed
at a localized stage, representing 71% of all tumors
among white women, 64% of all tumors among black
women, and 80% of all tumors among Asian/Pacific
Islander women (Table 6). Distant borderline tumors,
by contrast, were relatively more common among
black women than among white and Asian/Pacific
Islander women.
Hispanic, Not Hispanic
Age-specific incidence rates for ovarian cancer among
Hispanic women rose more gradually than rates
among women who were not Hispanic, peaking at
ages 80 – 84 years. Among patients ages 10 –29 years,
incidence rates among Hispanic women were higher
than rates among women who were not Hispanic,
whereas among women age  30 years, the incidence
rates among Hispanic women were lower than rates
among women who were not Hispanic (Fig. 3).
The age-adjusted incidence rate for malignant
ovarian cancer among Hispanic women (9.4 per
100,000) was 28% lower than among women who were
not Hispanic (13.0 per 100,000) (Table 7).
The age-specific incidence of borderline tumors
was higher among Hispanics than among women who
were not Hispanic until ages 25–29 years, when the
rates converged (Fig. 4). The incidence of borderline
tumors peaked among Hispanic women at ages 45– 49
years and then again at ages 70 –74 years. Among
women who were not Hispanic, the incidence of bor-
derline tumors peaked at ages 55–59 years.
TABLE 2
Borderlinea Ovarian Cancer Counts and Age-Adjusted Incidence
Ratesb by Race, Selected Areas in the U.S., 1992–1997c
Race Count Rated Lower CI Upper CI
White 7507 2.0 2.0 2.0
Black 517 1.2 1.1 1.3
American Indiane 12 - 0.6 2.3
Asian/Pacific Islander 305 1.4 1.2 1.6
All Racesf 8469 1.9 1.9 1.9
CI: 95% confidence interval.
a Borderline Malignant is equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462:
papillary serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystade-
noma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Source: North American Association of Central Cancer Registries file submissions as of December
1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta),
Florida, Idaho, Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit), Minnesota, Montana,
Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington
(Seattle), West Virginia, and Wisconsin.
d Rate is suppressed when count is 20.
e American Indian includes cases from Arizona and New Mexico only.
f Total includes 114 women with other or unknown race and 14 American Indian women in areas
outside Arizona and New Mexico.
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Hispanic women had a lower rate of borderline
tumors (1.7 per 100,000) compared with women who
were not Hispanic (2.0 per 100,000) (Table 8).
Serous carcinoma was the most common histo-
logic type of malignant ovarian cancer among women,
regardless of Hispanic ethnicity (Table 9). The rate of
unspecified tumor was similar in the two ethnic
groups. The risk of serous carcinoma was 38% lower
among Hispanic women than among women who
were not Hispanic. The rates for all histologic subtypes
TABLE 3
Malignanta Ovarian Cancer Counts and Age-Adjusted Incidence Ratesb by Histology and Race, Selected Areas in the U.S., 1992–1997c
IARC histology
White Black American Indiand Asian/Pacific Islander All racese
Count Rate
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI Count Ratef
Lower
CI
Upper
CI Count Ratef
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI
Carcinoma 48,406 11.9 11.8 12.0 2969 7.5 7.2 7.8 70 8.9 6.9 11.4 1421 7.5 7.1 7.9 53,314 11.4 11.3 11.5
Serous carcinoma 18,720 4.8 4.7 4.8 991 2.5 2.4 2.7 27 3.3 2.2 4.9 463 2.5 2.3 2.7 20,363 4.5 4.4 4.6
Mucinous carcinoma 4775 1.2 1.2 1.2 340 0.8 0.7 0.9 6 — 0.3 1.7 199 1.0 0.9 1.1 5374 1.2 1.1 1.2
Endometrioid carcinoma 5887 1.5 1.5 1.6 279 0.7 0.6 0.8 15 — 1.0 3.2 217 1.1 0.9 1.2 6467 1.4 1.4 1.5
Clear cell carcinoma 1923 0.5 0.5 0.5 76 0.2 0.1 0.2 3 — 0.1 1.1 137 0.7 0.6 0.8 2162 0.5 0.5 0.5
Adenocarcinoma, NOS 11,994 2.7 2.7 2.8 847 2.2 2.0 2.3 7 — 0.4 2.0 281 1.6 1.4 1.8 13,224 2.7 2.6 2.7
Other specified carcinomas 1176 0.3 0.3 0.3 85 0.2 0.2 0.3 2 — 0.0 1.1 35 0.2 0.1 0.3 1308 0.3 0.3 0.3
Unspecified carcinoma 3931 0.8 0.8 0.9 351 0.9 0.8 1.0 10 — 0.6 2.5 89 0.5 0.4 0.6 4416 0.8 0.8 0.9
Sex cord-stromal tumors 599 0.2 0.1 0.2 145 0.3 0.3 0.4 2 — 0.0 1.0 19 - 0.1 0.2 779 0.2 0.2 0.2
Germ cell tumors 1039 0.4 0.3 0.4 161 0.4 0.3 0.4 3 — 0.1 0.9 79 0.4 0.3 0.5 1304 0.4 0.3 0.4
Other specified tumor 1426 0.3 0.3 0.4 133 0.4 0.3 0.4 2 — 0.0 1.0 41 0.2 0.2 0.3 1612 0.3 0.3 0.4
Unspecified tumor 2026 0.4 0.4 0.4 181 0.4 0.4 0.5 4 — 0.1 1.3 36 0.2 0.1 0.3 2268 0.4 0.4 0.4
Total 53,496 13.1 13.0 13.2 3589 9.0 8.7 9.3 81 10.2 8.0 12.7 1596 8.4 8.0 8.9 59,277 12.6 12.5 12.7
IARC: International Agency for Research on Cancer; CI: 95% confidence interval; NOS: not otherwise specified.
a Malignant is not equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462: papillary serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystadenoma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Source: North American Association of Central Cancer Registries file submissions as of December 1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta), Florida, Idaho,
Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit), Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington (Seattle), West Virginia,
and Wisconsin.
d American Indian cases from Arizona and New Mexico only.
e Totals include 435 women with other or unknown race and 80 American Indian women in areas outside Arizona and New Mexico.
f Rate is suppressed when count is 20.
TABLE 4
Borderlinea Ovarian Cancer Counts and Age-Adjusted Incidence Ratesb by Race, Selected Areas in the U.S., 1992–1997c
Borderline White Black American Indiand Asian/Pacific Islander All racese
Low malignant
potential Count Rate
Lower
CI
Upper
CI Count Ratef
Lower
CI
Upper
CI Count Ratef
Lower
CI
Upper
CI Count Ratef
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI
Serous cystadenoma 1901 0.5 0.5 0.5 138 0.3 0.3 0.4 4 — 0.1 1.1 57 0.3 0.2 0.4 2131 0.5 0.5 0.5
Papillary cystadenoma 165 0.0 0.0 0.1 14 — 0.0 0.1 1 — 0.0 0.8 3 — 0.0 0.1 186 0.0 0.0 0.0
Papillary serous
cystadenoma 2661 0.7 0.7 0.7 237 0.5 0.5 0.6 4 — 0.1 1.2 75 0.3 0.2 0.4 3024 0.7 0.7 0.7
Mucinous cystadenoma 2572 0.7 0.7 0.7 120 0.3 0.2 0.3 3 — 0.1 1.1 160 0.8 0.6 0.9 2899 0.7 0.6 0.7
Papillary mucinous
cystadenoma 208 0.1 0.0 0.1 8 — 0.0 0.0 0 — 0.0 0.6 10 — 0.0 0.1 229 0.0 0.0 0.1
Total 7507 2.0 2.0 2.0 517 1.2 1.1 1.3 12 — 0.6 2.3 305 1.4 1.2 1.6 8469 1.9 1.9 1.9
CI: 95% confidence interval.
a Borderline Malignant is equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462: papillary serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystadenoma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Source: North American Association of Central Cancer Registries file submissions as of December 1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta), Florida, Idaho,
Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit), Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington (Seattle), West Virginia,
and Wisconsin.
d American Indian cases from Arizona and New Mexico only.
e Row totals include 114 women with other or unknown race and American Indian women outside Arizona and New Mexico.
f Rate is suppressed when count is 20.
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of malignant tumors were lower among Hispanic
women than among women who were not Hispanic,
with the exception of germ cell tumors.
Papillary serous cystadenoma was the most com-
mon histologic type of borderline tumor among His-
panic women and women who were not Hispanic,
followed by mucinous cystadenoma and serous cysta-
denoma (Table 10).
Hispanic women had a lower rate of localized,
regional, and distant stages of malignant ovarian can-
cer compared with women who were not Hispanic
(Table 11). Hispanic women also had a lower rate of
unstaged ovarian cancer. Distant cancer was the most
common stage at diagnosis in both Hispanic women
and women who were not Hispanic. The rate of dis-
tant malignant ovarian cancer relative to the overall
rate was similar in Hispanic women (62%) and women
who were not Hispanic (60%).
TABLE 6
Borderlinea Ovarian Cancer Counts and Age-Adjusted Incidence Ratesb by Summary Stagec and Race, Selected Areas in the U.S., 1992–1997d
Stage
White Black American Indiane Asian/Pacific Islander All Racesf
Count Rate
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI Count Rateg
Lower
CI
Upper
CI Count Rateg
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI
Localized 4949 1.2 1.2 1.3 335 0.7 0.6 0.8 8 — 0.3 1.7 222 0.8 0.7 0.9 5590 1.2 1.1 1.2
Regional 553 0.1 0.1 0.2 54 0.1 0.1 0.1 2 — 0.0 0.9 19 — 0.0 0.1 642 0.1 0.1 0.1
Distant 863 0.2 0.2 0.2 85 0.2 0.1 0.2 2 — 0.0 0.9 28 0.1 0.1 0.1 987 0.2 0.2 0.2
Unstaged 239 0.1 0.1 0.1 30 0.1 0.0 0.1 0 — 0.0 0.6 5 — 0.0 0.0 288 0.1 0.1 0.1
Total 6604 1.7 1.6 1.7 504 1.1 1.0 1.2 12 — 0.6 2.3 274 1.0 0.9 1.1 7507 1.6 1.5 1.6
CI: 95% confidence interval.
a Borderline Malignant is equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462: papillary serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystadenoma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Excludes data from Minnesota for 1992–1994 and California outside the Los Angeles and Greater Bay Area for 1994 –1997.
d Source: North American Association of Central Cancer Registries file submissions as of December 1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta), Florida, Idaho,
Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit), Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington (Seattle), West Virginia,
and Wisconsin.
e American Indian cases from Arizona and New Mexico only.
f Totals include 100 women with other or unknown race and 13 American Indian women in areas outside Arizona and New Mexico.
g Rate is suppressed when count is 20.
TABLE 5
Malignanta Ovarian Cancer Counts and Age-Adjusted Incidence Ratesb by Summary Stagec and Race, Selected Areas in the U.S., 1992–1997d
Stage
White Black American Indiane Asian/Pacific Islander All racesf
Count Rate
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI Count Rateg
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI
Localized 9175 2.3 2.3 2.4 612 1.4 1.3 1.5 9 — 0.5 2.1 378 1.5 1.4 1.7 10,288 2.2 2.2 2.3
Regional 6352 1.5 1.5 1.6 429 1.0 0.9 1.1 7 — 0.4 1.9 166 0.7 0.6 0.8 7019 1.5 1.4 1.5
Distant 28,244 6.6 6.6 6.7 2036 4.8 4.6 5.0 58 7.3 5.5 9.5 748 3.3 3.1 3.6 31,288 6.3 6.3 6.4
Unstaged 4,575 0.9 0.9 1.0 387 0.9 0.8 1.0 7 — 0.4 1.9 76 0.3 0.3 0.4 5116 0.9 0.9 1.0
Total 48,346 11.5 11.4 11.6 3464 8.1 7.8 8.3 81 10.2 8.0 12.7 1368 5.9 5.6 6.2 53,711 10.9 10.8 11.0
CI: 95% confidence interval.
a Malignant is not equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462: papillary serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystadenoma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Excludes data from Minnesota for 1992–1994 and California outside the Los Angeles and Greater Bay Area for 1994 –1997.
d Source: North American Association of Central Cancer Registries file submissions as of December 1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta) Florida, Idaho,
Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit) Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington (Seattle) West Virginia, and
Wisconsin.
e American Indian cases from Arizona and New Mexico only.
f Totals include 383 women with other or unknown race and 69 American Indian women in areas outside Arizona and New Mexico.
g Rate is suppressed when count is 20.
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The relative percentage of localized borderline tu-
mors was 75% among Hispanic women and 73%
among women who were not Hispanic (Table 12). The
relative percentages of regional and distant borderline
tumors also were similar between Hispanic women
and women who were not Hispanic.
DISCUSSION
This analysis confirms previous reports2–4,6–8 that white
women in the U.S. are at a substantially higher risk for
ovarian cancer compared with women of other racial
and ethnic groups, especially women of Asian/Pacific
Islander ancestry. Ethnic-specific incidence patterns in
this analysis of data from 1992–1997 were somewhat
lower than those reported by the Surveillance, Epidemi-
ology, and End Results (SEER) program for the years
1988–1992.3 For example, the ovarian cancer rate among
white women in the SEER program was 15.8 per 100,000
and that among black women was 10.2 per 100,000 com-
pared with NAACCR rates of 13.1 per 100,000 and 9.0 per
100,000, respectively, for white and black women.
The rate of ovarian cancer among American Indi-
ans in New Mexico was 17.5 per 100,000 for 1988 –
19922 compared with 10.2 per 100,000 between 1992–
1997 for American Indians in New Mexico and Arizona
combined. This dramatic decline in ovarian cancer
incidence could be artifactual, resulting from tribal
differences in the rates of ovarian cancer between
these two states. Although based on a small number of
cases, this decline nonetheless should be monitored to
determine whether it reflects a real change in commu-
nity behavior, such as heightened acceptance of oral
contraceptive pills, or an increased prevalence of oo-
phorectomy or tubal ligation.
To our knowledge, few analytic studies have been
conducted to explain the increased risk of ovarian
cancer among white women compared with other ra-
cial and ethnic groups.6 –10 Combining data from
seven case– control studies, John et al.6 reported that
reproductive factors could account for only 9 –16% of
FIGURE 3. Age-specific incidence rates for malignant ovarian cancer by
Hispanic ethnicity, North American Association of Central Cancer Registries
(NAACCR) U.S. combined areas, 1992–1997.
TABLE 7
Malignanta Ovarian Cancer Counts and Age-Adjusted Incidence
Ratesb by Hispanic Ethnicityc, Selected Areas in the U.S., 1992–1997d
Ethnicity Count Rate
Lower
CI
Upper
CI
Hispanic 2978 9.4 9.0 9.7
Not Hispanic 31,715 13.0 12.9 13.2
Totale 35,218 12.8 12.6 12.9
CI: 95% confidence interval.
a Malignant is not equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462: papillary
serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystadenoma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Includes cases from Arizona, California, Colorado, Connecticut, Florida, Illinois, New Mexico, Utah,
and Washington (Seattle) only.
d Source: North American Association of Central Cancer Registries file submissions as of December
1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta),
Florida, Idaho, Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit), Minnesota, Montana,
Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington
(Seattle), West Virginia, and Wisconsin.
e Total includes 525 with unknown Hispanic ethnicity.
FIGURE 4. Age-specific incidence rates for borderline ovarian cancer by
Hispanic ethnicity, North American Association of Central Cancer Registries
(NAACCR) U.S. combined areas, 1992–1997.
TABLE 8
Borderlinea Ovarian Cancer Counts and Age-Adjusted Incidence
Ratesb by Hispanic Ethnicityc, Selected Areas in the U.S., 1992–1997d
Ethnicity Count Rate
Lower
CI
Upper
CI
Hispanic 687 1.7 1.6 1.9
Not Hispanic 4391 2.0 1.9 2.0
Totale 5166 2.0 1.9 2.0
CI: 95% confidence interval.
a Borderline Malignant is equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462:
papillary serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystade-
noma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Includes cases from Arizona, California, Colorado, Connecticut, Florida, Illinois, New Mexico, Utah,
and Washington (Seattle) only.
d Source: North American Association of Central Cancer Registries file submissions as of December
1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta),
Florida, Idaho, Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit), Minnesota, Montana,
Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington
(Seattle), West Virginia, and Wisconsin.
e Total includes 88 with unknown Hispanic ethnicity.
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the difference in the risk of ovarian cancer noted be-
tween white and black women in the U.S. In a recent
population-based case– control study in Pittsburgh,
Pennsylvania, Ness et al.7 found that black women
were more likely than white women to have experi-
enced five or more pregnancies and undergone a hys-
terectomy, and less likely to have a family history of
ovarian cancer. Although the risk for ovarian cancer in
Asian/Pacific Islander women in the current analysis
was lower than that in white American women, this
TABLE 9
Malignanta Ovarian Cancer Counts, and Age-Adjusted Incidence Ratesb by Histology and Hispanic Ethnicityc, Selected Areas in the U.S.,
1992–1997d
IARC histology
Hispanic Not Hispanic Totale
Count Rate
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI
Carcinoma 2558 8.3 7.9 8.6 28,706 11.8 11.6 11.9 31,743 11.5 11.4 11.7
Serous carcinoma 890 2.9 2.7 3.1 11,024 4.7 4.6 4.8 12,094 4.5 4.5 4.6
Mucinous carcinoma 322 1.0 0.8 1.1 2762 1.2 1.1 1.2 3129 1.2 1.1 1.2
Endometrioid carcinoma 294 0.9 0.8 1.1 3427 1.5 1.4 1.5 3783 1.4 1.4 1.5
Clear cell carcinoma 93 0.3 0.2 0.4 1129 0.5 0.5 0.5 1251 0.5 0.5 0.5
Adenocarcinoma, NOS 621 2.1 1.9 2.2 7151 2.7 2.7 2.8 7885 2.7 2.6 2.8
Other specified carcinomas 93 0.3 0.2 0.3 690 0.3 0.3 0.3 792 0.3 0.3 0.3
Unspecified carcinoma 245 0.8 0.7 0.9 2523 0.9 0.9 0.9 2809 0.9 0.9 0.9
Sex cord-stromal tumors 48 0.1 0.1 0.2 379 0.2 0.2 0.2 440 0.2 0.2 0.2
Germ cell tumors 203 0.5 0.4 0.5 600 0.4 0.3 0.4 814 0.4 0.4 0.4
Other specified tumors 70 0.2 0.2 0.3 909 0.4 0.3 0.4 984 0.4 0.3 0.4
Unspecified tumors 99 0.3 0.3 0.4 1121 0.3 0.3 0.4 1237 0.3 0.3 0.4
Ovary 2978 9.4 9.0 9.7 31,715 13.0 12.9 13.2 35,218 12.8 12.6 12.9
IARC: International Agency for Research on Cancer; CI: 95% confidence interval; NOS: not otherwise specified.
a Malignant is not equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462: papillary serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystadenoma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Includes cases from Arizona, California, Colorado, Connecticut, Florida, Illinois, New Mexico, Utah, and Washington (Seattle) only.
d Source: North American Association of Central Cancer Registries file submissions as of December 1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta), Florida, Idaho,
Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit), Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington (Seattle), West Virginia,
and Wisconsin.
e Total includes 613 with unknown Hispanic ethnicity.
TABLE 10
Borderlinea Ovarian Cancer Counts and Age-Adjusted Incidence Ratesb by Histology and Hispanic Ethnicityc, Selected Areas in the U.S.,
1992–1997d
IARC histology
Hispanic Not Hispanic Totale
Count Ratef
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI
Serous cytadenoma 192 0.5 0.4 0.6 1065 0.5 0.4 0.5 1284 0.5 0.5 0.5
Papillary cytadenoma 18 — 0.0 0.1 92 0.0 0.0 0.1 112 0.0 0.0 0.1
Papillary serous cystadenoma 262 0.6 0.6 0.7 1611 0.7 0.7 0.8 1906 0.7 0.7 0.8
Mucinous cystadenoma 194 0.5 0.4 0.6 1507 0.7 0.6 0.7 1725 0.7 0.6 0.7
Papillary mucinous cystadenoma 21 0.1 0.0 0.1 116 0.0 0.0 0.1 139 0.1 0.0 0.1
Total 687 1.7 1.6 1.9 4391 2.0 1.9 2.0 5166 2.0 1.9 2.0
IARC: International Agency for Research on Cancer; CI: 95% confidence interval.
a Borderline Malignant is equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462: papillary serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystadenoma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Includes cases from Arizona, California, Colorado, Connecticut, Florida, Illinois, New Mexico, Utah, and Washington (Seattle) only.
d Source: North American Association of Central Cancer Registries file submissions as of December 1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta), Florida, Idaho,
Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit), Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington (Seattle), West Virginia,
and Wisconsin.
e Total includes 88 cases with unknown Hispanic ethnicity.
f Rate is suppressed when count is 20.
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was true only after the age of 25 years. Herrinton et al.8
reported that premenopausal Asian-American women
(age  50 years) tended to have relatively higher ovar-
ian cancer rates than postmenopausal Asian-Ameri-
can women when compared with white women of the
same menopausal status. Age-specific incidence rates
in the NAACCR dataset were found to be lower among
black women than among Asian/Pacific Islander
women up to the age of 60 years, suggesting age-
specific differences in risk factors between race
groups. Premenopausal ovarian cancer is more likely
to have a genetic basis,11 but nonhereditary factors
may play a more important role in explaining these
age-related incidence patterns.
Ovarian cancer incidence rates among Hispanic
women were reported to be lower than among women
who were not Hispanic. The rate of ovarian cancer in
Hispanic women (9.4 per 100,000) was comparable to
that calculated for Hispanics in the SEER program
(11.4 per 100,000)3 and California (9.0 –9.9 per 100,000)
TABLE 11
Malignanta Ovarian Cancer Counts and Age-Adjusted Incidence Ratesb by Summary Stagec and Hispanic Ethnicityd, Selected Areas in the U.S.,
1992–1997e
Stage
Hispanic Not Hispanic Totalf
Count Rate
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI
Localized 540 1.3 1.2 1.4 5003 2.1 2.0 2.1 5639 2.0 1.9 2.0
Regional 243 0.6 0.6 0.7 3192 1.3 1.2 1.3 3505 1.2 1.2 1.2
Distant 1506 4.3 4.1 4.6 16,395 6.4 6.3 6.5 18,655 6.3 6.2 6.3
Unstaged 237 0.7 0.6 0.8 2629 0.9 0.9 0.9 2924 0.9 0.9 0.9
Totalf 2526 6.9 6.6 7.2 27,719 10.6 10.5 10.8 30,723 10.3 10.2 10.5
CI: 95% confidence interval.
a Malignant is not equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462: papillary serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystadenoma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Excludes data from Minnesota for 1992–1994 and California, except the Los Angeles and Greater Bay Area for 1994 –1997.
d Includes cases from Arizona, California, Colorado, Connecticut, Florida, Illinois, New Mexico, Utah, and Washington (Seattle) only.
e Source: North American Association of Central Cancer Registries file submissions as of December 1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta), Florida, Idaho,
Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit), Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington (Seattle), West Virginia,
and Wisconsin.
f Totals include 478 women with unknown Hispanic ethnicity.
TABLE 12
Borderlinea Ovarian Cancer Counts and Age-Adjusted Incidence Ratesb by Summary Stagec and Hispanic Ethnicityd, Selected Areas in the U.S.,
1992–1997e
Stage
Hispanic Not Hispanic Totalf
Count Rateg
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI Count Rate
Lower
CI
Upper
CI
Localized 442 0.9 0.8 1.0 2762 1.1 1.1 1.2 3255 1.1 1.1 1.2
Regional 51 0.1 0.1 0.1 329 0.1 0.1 0.1 391 0.1 0.1 0.1
Distant 63 0.1 0.1 0.2 577 0.2 0.2 0.3 648 0.2 0.2 0.2
Unstaged 15 - 0.0 0.1 79 0.0 0.0 0.0 98 0.0 0.0 0.0
Totalf 571 1.2 1.1 1.3 3747 1.5 1.5 1.6 4392 1.5 1.5 1.5
CI: 95% confidence interval.
a Borderline Malignant is equal to: 8442: serous cystadenoma; 8451: papillary cystadenoma; 8462: papillary serous cystadenoma; 8472: mucinous cystadenoma; and 8473: papillary mucinous cystadenoma.
b Rates are per 100,000 and age-adjusted to the 1970 U.S. standard population.
c Excludes data from Minnesota for 1992–1994 and California, except the Los Angeles and Greater Bay Area for 1994 –1997.
d Includes cases from Arizona, California, Colorado, Connecticut, Florida, Illinois, New Mexico, Utah, and Washington (Seattle) only.
e Source: North American Association of Central Cancer Registries file submissions as of December 1999 from Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Georgia (Metro Atlanta), Florida, Idaho,
Illinois, Iowa, Kentucky, Louisiana, Michigan (Metro Detroit), Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Rhode Island, Utah, Washington (Seattle), West Virginia,
and Wisconsin.
f Totals include 74 women with unknown Hispanic ethnicity.
g Rate is suppressed when count is 20.
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and New Mexico (8.6 per 100,000),2 but was substan-
tially higher than the rate among Hispanics in Puerto
Rico (5.2 per 100,000) and the majority of Latin Amer-
ican countries.2 California contributed nearly 56% of
the Hispanic cases in the NAACCR file, leading us to
anticipate good concordance between our rates and
the Hispanic ovarian cancer incidence in this state.
The birth rate among Hispanic women reportedly is
higher than among non-Hispanic women and this
would reduce the risk of ovarian cancer.12 However,
the lower incidence of ovarian cancer among Hispanic
women compared with women who were not His-
panic must be evaluated with some caution because
the large percentage of missing data regarding His-
panic ethnicity reduces the representativeness of
these data. Nevertheless, it is reassuring that the over-
all incidence rate for the subgroup of women with
Hispanic identifiers (12.8 per 100,000) was similar to
the rate in the entire sample, including those women
with unknown Hispanic ethnicity (12.6 per 100,000).
The histologic distribution of malignant ovarian can-
cer was consistent with distributions reported in other case
series.13 Serous carcinomas were relatively more common
among white women and clear cell and endometrioid car-
cinomas were relatively more common among Asian/Pa-
cific Islanders compared with other racial and ethnic
groups. Differences in histologic patterns suggest heteroge-
neity in risk factors, such as genetic predisposition, for
epithelial ovarian cancer occurring among these popula-
tions. The PTEN tumor suppressor gene has been linked to
the malignant transformation of benign endometrial cysts
to endometrioid and clear cell carcinomas of the ovary.14
Histologic and molecular genetic studies also have pro-
vided evidence that endometrioid and clear cell carcino-
mas may arise through malignant transformation of endo-
metriotic lesions.15 An inverse relation between tubal
ligation and ovarian cancer risk may be limited to these
histologic types,16 although we have no data concerning
ethnic-specific rates for this procedure. These observations
indicate a unique pathogenesis of ovarian cancer in Asian/
Pacific Islander women.
The high percentage of black women with unspecified
tumors suggests that these women may not be receiving
the same level of diagnostic service as women of other
races or ethnicities. The relatively high incidence of germ
cell tumors among Hispanic women compared with non-
Hispanic women has not to our knowledge been observed
previously and may result from ethnic differences in early-
age or maternal exposures.
Metastatic disease was the most common stage at
diagnosis for all ethnic groups, but particularly for
American Indian women, among whom approxi-
mately 63% of age-adjusted ovarian cancer was diag-
nosed at a distant stage, underscoring the need to
provide state-of-the-art gynecology and oncology ser-
vices to Native Americans. By contrast, Asian/Pacific
Islander women were found to have the highest pro-
portion of localized ovarian cancer (approximately
33%), indicating that these groups may have different
risk factors or proportionately higher and earlier ac-
cess to health services and diagnostic workup.
Women with epithelial tumors of low malignant po-
tential (borderline) were diagnosed at younger ages and
less advanced stages compared with women with malig-
nant tumors. The race- and ethnic-specific incidence of
borderline tumors closely paralleled that of malignant
tumors, implying common risk factors. Indeed, epide-
miologic studies support the notion that the etiology of
borderline tumors and malignant tumors is similar.17 Of
interest in our analysis were the substantial racial and
ethnic variations in the histology of borderline tumors.
The rate of mucinous cystadenoma was higher and the
rate of serous cystadenoma was lower among Asian/
Pacific Islander women compared with other groups.
This observation is compatible with the concept that, at
least in some instances, borderline tumors represent a
transitional form to higher grade malignancy as a result
of clonal expansion.18 Molecular analysis has revealed
that borderline mucinous and serous tumors have ge-
netic features, such as p53 and Ki-RAS mutations, that
are associated with malignancy.19
Several methodologic issues must be considered
in reviewing these incidence data.
Proper assignment of racial or ethnic classifica-
tion in the cancer registry is dependent on the accu-
racy of the medical record or other vital records that
are primary sources of information.20 Computation of
valid cancer rates is dependent on the accuracy of the
census counts and the comparability of racial desig-
nations used in the numerator and the denominator.
If case ascertainment for a racial group is less com-
plete than the census counts, the resulting rates will
be underestimated. Aside from problems with racial
and ethnic misclassification, this analysis is limited by
our inability to examine ovarian cancer incidence
among specific subgroups of Hispanic, American In-
dian, or Asian/Pacific Islander women. For example,
approximately 60% of Hispanics in the U.S. are of
Mexican descent, and many of these women reside in
California and Texas.21 Hispanics are the fastest grow-
ing minority in the U.S. and it is believed they will
soon become the largest minority group in the na-
tion.22 American Indian and Asian/Pacific Islanders
are equally heterogeneous populations of women who
may have distinct ovarian cancer incidence patterns
within subgroups that were missed in this analysis.3 In
the next year, census data will be available to allow the
calculation of more precise ethnic-specific rates.
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Ovarian cancer incidence may be affected by
trends in the performance of hysterectomy and oo-
phorectomy. Between 1991–1994, the rate of total hys-
terectomy in the U.S. decreased from 25.7 to 20.5 per
10,000 females and the rate of supracervical hysterec-
tomy increased from 0.16 to 0.41 per 10,000 fe-
males.23–25 To our knowledge, complete and accurate
population data regarding the proportion of women
who have undergone oophorectomy by age, race, and
ethnicity (which would be potentially useful for ad-
justing ovarian cancer incidence rates) currently are
lacking. Hysterectomy and oophorectomy rates may
vary by race, ethnicity, socioeconomic status, access
to health care, geographic region of the U.S., and other
factors that may influence ovarian cancer incidence
rates among specific groups of women.
The current analysis included clinical information
from a large number of women diagnosed with ovarian
cancer in the U.S. during the past decade. Observed
ethnic and racial variations in ovarian cancer incidence
were found to be in agreement with other analyses in the
U.S. demonstrating higher risk among white women and
women who were not Hispanic than among black,
American Indian, Asian/Pacific Islander, and Hispanic
women. Future analyses of these data will include sep-
arate rates for Asian/Pacific Islander women because
these groups have distinct reproductive histories, exog-
enous hormone use, genetic background, and other fac-
tors that may influence the incidence of ovarian cancer.
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